Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Custom recombinant protein production plays a major role in advanced healthcare and is the most efficient technique used in life sciences. Recombinant proteins are used in a wide range of applications in research, biotechnology, and medicine. Increasing funding in the field of life sciences is expected to propel growth of the custom recombinant protein production services market. Recombinant protein is a manipulated form of protein, which is encoded by genes. It is used in production of large quantities of protein, which is further used for manufacturing of therapeutic commercial products. Increasing government initiatives and funding in the field of life sciences is expected to boost growth of the market. For instance, Life Sciences Greenhouse of Central Pennsylvania offers early stage funding of up to US$ 1-2 million in the form of convertible debt or equity financing to viable life sciences companies, which have significant potential for commercial growth.
Global Custom Recombinant Protein Production Services Market - Impact of Coronavirus (COVID-19) Pandemic
The spread of the novel coronavirus has hampered growth of the pharmaceutical industry. In December 2019, in China’s Wuhan City, a cluster of pneumonia cases were reported by Chinese health authorities. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe, thus causing a concerning number of fatalities. In March 2020, the World Health Organization (WHO) declared the COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed down growth of the healthcare sector and led to a disturbance in the supply chain.
Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing its supply chain operations. The slowdown of the healthcare companies’ supply chain has also impacted negatively on growth of the global custom recombinant protein production services market.
The global custom recombinant protein production services market size is estimated to be valued at US$ 3575.3 million in 2020 and is expected to exhibit a CAGR of 11.2% over the forecast period (2020 – 2027).
Figure 1. Global Custom Recombinant Protein Production Services Market Share (%) Analysis, By Expression System, 2020
Global Custom Recombinant Protein Production Services Market - Restraints
However, high cost of recombinant protein for particular requirement is expected to hinder the market growth. The price of protein synthesis services range from US$ 3 to US$ 160 per amino acid depending upon the purity of the desired product. Moreover, the price of recombinant protein production services varies from US$ 500 to US$ 5,000 per milligram depending upon the protein production expression systems, species of the proteins, and the family to which these recombinant proteins belong.
Custom Recombinant Protein Production Services Market Report Coverage
||Market Size in 2019:
||US$ 2,338.3 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 7,517.2 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Expression System: Mammalian, Bacteria, Insect, Yeast, Others.
- By End User: Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations, Others.
GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience, Inc., BPS Bioscience, Inc., ProteoGenix, Kempbio, Inc., Novoprotein, Premas Biotech, Trenzyme GmbH, Atum, Novus Biologicals, LLC, Icosagen AS, LakePharma, Inc., Proteos, Inc., Aldevron, Sino Biological Inc., and SignalChem Lifesciences Corporation
- Increasing research and development and product launches
|Restraints & Challenges:
- High cost of recombinant protein for particular requirement
Global Custom Recombinant Protein Production Services Market – Regional Analysis
On the basis of region, the global custom recombinant protein production services market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Increasing research and development and product launches in North America is expected to bolster the market growth. For instance, in 2020, researcher from University of California - San Diego found that genome-editing techniques could eliminate up to 70 percent of the contaminating protein by mass in recombinant-protein drugs produced by the workhorses of mammalian cells –such as Chinese Hamster Ovary (CHO) cells. With such advanced research findings, this helps to boost the production services of custom recombinant protein.
Moreover, the companies in the region are focused on adopting strategic acquisitions to expand their geographic presence. For instance, in 2017, Eurofins Scientific acquired DiscoverX to improve research productivity and accelerate the discovery and development of new drugs. The acquisition is also expected to create a robust portfolio of kinase products and services in the market.
Furthermore, in December 2019, iBio, Inc. unveiled the FastGlycaneering Development Service, which has an array of new glycosylation technologies for engineering high-performance recombinant proteins. By using iBio’s plant-based manufacturing services, the biopharmaceutical companies and biosimilar producers are able to take the advantage of low-cost afucosylation controls, oligomannose modification capabilities, and more custom glycosylation used for rapidly develop best quality novel antibody and biosimilars drugs.
Figure 2. Global Custom Recombinant Protein Production Services Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Custom Recombinant Protein Production Services Market - Competitive Landscape
Key players operating in the global custom recombinant protein production services market include GenScript Biotech Corporation, Applied Biological Materials Inc., Eurofins Pharma Discovery Services, Abgent, OriGene Technologies, Inc., Crown Bioscience, Inc., BPS Bioscience, Inc., ProteoGenix, Kempbio, Inc., Novoprotein, Premas Biotech, Trenzyme GmbH, Atum, Novus Biologicals, LLC, Icosagen AS, LakePharma, Inc., Proteos, Inc., Aldevron, Sino Biological Inc., and SignalChem Lifesciences Corporation.